Last reviewed · How we verify
Zepatier Oral Product
Zepatier Oral Product is a NS5A inhibitor, NS3/4A protease inhibitor Small molecule drug developed by Kaohsiung Medical University Chung-Ho Memorial Hospital. It is currently in Phase 3 development for Chronic hepatitis C virus (HCV) infection, genotype 1 or 4, Chronic HCV infection, genotype 1a or 1b, without cirrhosis or with compensated cirrhosis. Also known as: Zepatier.
Zepatier is a combination of elbasvir and grazoprevir, which are inhibitors of the hepatitis C virus NS5A and NS3/4A proteases, respectively.
Zepatier is a combination of elbasvir and grazoprevir, which are inhibitors of the hepatitis C virus NS5A and NS3/4A proteases, respectively. Used for Chronic hepatitis C virus (HCV) infection, genotype 1 or 4, Chronic HCV infection, genotype 1a or 1b, without cirrhosis or with compensated cirrhosis.
At a glance
| Generic name | Zepatier Oral Product |
|---|---|
| Also known as | Zepatier |
| Sponsor | Kaohsiung Medical University Chung-Ho Memorial Hospital |
| Drug class | NS5A inhibitor, NS3/4A protease inhibitor |
| Target | NS5A, NS3/4A protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Elbasvir and grazoprevir work by binding to the NS5A and NS3/4A proteases of the hepatitis C virus, preventing the virus from replicating. This leads to a reduction in viral load and an improvement in liver function.
Approved indications
- Chronic hepatitis C virus (HCV) infection, genotype 1 or 4
- Chronic HCV infection, genotype 1a or 1b, without cirrhosis or with compensated cirrhosis
Common side effects
- Fatigue
- Headache
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- Pembrolizumab (MK-3475) in Hepatocellular Carcinoma (PHASE2)
- Zepatier in Patients with Substance Use
- HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant (PHASE4)
- Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients (PHASE1, PHASE2)
- Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079) (PHASE2)
- Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication (PHASE4)
- Transplanting Hepatitis C Lungs Into Negative Lung Recipients (PHASE1, PHASE2)
- Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zepatier Oral Product CI brief — competitive landscape report
- Zepatier Oral Product updates RSS · CI watch RSS
- Kaohsiung Medical University Chung-Ho Memorial Hospital portfolio CI
Frequently asked questions about Zepatier Oral Product
What is Zepatier Oral Product?
How does Zepatier Oral Product work?
What is Zepatier Oral Product used for?
Who makes Zepatier Oral Product?
Is Zepatier Oral Product also known as anything else?
What drug class is Zepatier Oral Product in?
What development phase is Zepatier Oral Product in?
What are the side effects of Zepatier Oral Product?
What does Zepatier Oral Product target?
Related
- Drug class: All NS5A inhibitor, NS3/4A protease inhibitor drugs
- Target: All drugs targeting NS5A, NS3/4A protease
- Manufacturer: Kaohsiung Medical University Chung-Ho Memorial Hospital — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Chronic hepatitis C virus (HCV) infection, genotype 1 or 4
- Indication: Drugs for Chronic HCV infection, genotype 1a or 1b, without cirrhosis or with compensated cirrhosis
- Also known as: Zepatier
- Compare: Zepatier Oral Product vs similar drugs
- Pricing: Zepatier Oral Product cost, discount & access